Found: 64
Select item for more details and to access through your institution.
Melanoma medicine: New drugs for melanoma and the role of the general practitioner.
- Published in:
- Australian Journal of General Practice, 2024, v. 53, n. 9, p. 619, doi. 10.31128/ajgp-01-24-7129
- By:
- Publication type:
- Article
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
- Published in:
- Oncogenesis, 2024, v. 13, n. 1, p. 1, doi. 10.1038/s41389-024-00511-8
- By:
- Publication type:
- Article
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36979-y
- By:
- Publication type:
- Article
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 8, p. e2327145, doi. 10.1001/jamanetworkopen.2023.27145
- By:
- Publication type:
- Article
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
- Published in:
- Nature Communications, 2014, v. 5, n. 12, p. 5694, doi. 10.1038/ncomms6694
- By:
- Publication type:
- Article
Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.
- Published in:
- Journal of Medical Imaging & Radiation Oncology, 2021, v. 65, n. 6, p. 760, doi. 10.1111/1754-9485.13243
- By:
- Publication type:
- Article
Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
- Published in:
- ANZ Journal of Surgery, 2023, v. 93, n. 1/2, p. 235, doi. 10.1111/ans.18219
- By:
- Publication type:
- Article
Melanoma management in the 21st century: a change in paradigm.
- Published in:
- ANZ Journal of Surgery, 2021, v. 91, n. 12, p. 2557, doi. 10.1111/ans.17356
- By:
- Publication type:
- Article
Hypermethylation of Circulating Free DNA in Cutaneous Melanoma.
- Published in:
- Applied Sciences (2076-3417), 2019, v. 9, n. 23, p. 5074, doi. 10.3390/app9235074
- By:
- Publication type:
- Article
Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 3, p. 1857, doi. 10.1245/s10434-023-14526-9
- By:
- Publication type:
- Article
ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 11, p. 6109, doi. 10.1245/s10434-021-10489-x
- By:
- Publication type:
- Article
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
- Published in:
- Frontiers in Endocrinology, 2021, v. 12, p. 1, doi. 10.3389/fendo.2021.764138
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitor Toxicity.
- Published in:
- Current Oncology Reports, 2018, v. 20, n. 9, p. 1, doi. 10.1007/s11912-018-0718-6
- By:
- Publication type:
- Article
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
- Published in:
- Molecular Oncology, 2014, v. 8, n. 3, p. 544, doi. 10.1016/j.molonc.2014.01.003
- By:
- Publication type:
- Article
Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2022, v. 107, n. 5, p. 1843, doi. 10.1210/clinem/dgac059
- By:
- Publication type:
- Article
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
- Published in:
- Strahlentherapie und Onkologie, 2021, v. 197, n. 12, p. 1104, doi. 10.1007/s00066-021-01798-x
- By:
- Publication type:
- Article
Immune‐Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. e1216, doi. 10.1002/onco.13776
- By:
- Publication type:
- Article
The Impact of Nonsteroidal Anti‐Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti‐PD‐1 Therapy in Advanced Melanoma.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. e602, doi. 10.1634/theoncologist.2019-0518
- By:
- Publication type:
- Article
Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0085004
- By:
- Publication type:
- Article
Is there a role for combined anti–PD‐1/CTLA‐4 checkpoint blockade in the management of advanced biliary tract cancers?
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 7, p. 1129, doi. 10.1002/cncr.34660
- By:
- Publication type:
- Article
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2020, v. 33, n. 2, p. 358, doi. 10.1111/pcmr.12831
- By:
- Publication type:
- Article
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies.
- Published in:
- Pigment Cell & Melanoma Research, 2019, v. 32, n. 4, p. 553, doi. 10.1111/pcmr.12775
- By:
- Publication type:
- Article
Oncogenic signaling in uveal melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 6, p. 661, doi. 10.1111/pcmr.12708
- By:
- Publication type:
- Article
Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 4, p. 509, doi. 10.1111/pcmr.12682
- By:
- Publication type:
- Article
Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2018, v. 31, n. 3, p. 404, doi. 10.1111/pcmr.12675
- By:
- Publication type:
- Article
Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.
- Published in:
- Pigment Cell & Melanoma Research, 2017, v. 30, n. 1, p. 68, doi. 10.1111/pcmr.12557
- By:
- Publication type:
- Article
Residual FDG- PET metabolic activity in metastatic melanoma patients with prolonged response to anti- PD-1 therapy.
- Published in:
- Pigment Cell & Melanoma Research, 2016, v. 29, n. 5, p. 572, doi. 10.1111/pcmr.12503
- By:
- Publication type:
- Article
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2016, v. 12, p. 5, doi. 10.1111/ajco.12656
- By:
- Publication type:
- Article
Musculoskeletal immune‐related adverse events with the use of checkpoint inhibitors in malignancy.
- Published in:
- Internal Medicine Journal, 2022, v. 52, n. 5, p. 818, doi. 10.1111/imj.15123
- By:
- Publication type:
- Article
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients.
- Published in:
- Biomarker Research, 2017, v. 5, p. 1, doi. 10.1186/s40364-017-0112-9
- By:
- Publication type:
- Article
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.
- Published in:
- Biomarker Research, 2017, v. 5, p. 1, doi. 10.1186/s40364-017-0098-3
- By:
- Publication type:
- Article
Telehealth follow‐up consultations for melanoma patients during the COVID‐19 pandemic: Patient and clinician satisfaction.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 23, p. 21373, doi. 10.1002/cam4.6679
- By:
- Publication type:
- Article
Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.820510
- By:
- Publication type:
- Article
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.765608
- By:
- Publication type:
- Article
Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-16276-8
- By:
- Publication type:
- Article
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-15726-7
- By:
- Publication type:
- Article
VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5012, doi. 10.3390/cancers15205012
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4345, doi. 10.3390/cancers13174345
- By:
- Publication type:
- Article
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3186, doi. 10.3390/cancers13133186
- By:
- Publication type:
- Article
Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1740, doi. 10.3390/cancers13071740
- By:
- Publication type:
- Article
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3374, doi. 10.3390/cancers12113374
- By:
- Publication type:
- Article